09:42 AM EDT, 07/10/2025 (MT Newswires) -- Soleno Therapeutics ( SLNO ) said Thursday it has priced an underwritten public offering of about 2.4 million common shares at $85 each for gross proceeds of roughly $200 million.

The underwriters were granted a 30-day option to buy up to an additional 352,941 shares at the public offering price, the company said.

The offering will likely close Friday, Soleno Therapeutics ( SLNO ) said, adding that the proceeds would be allocated toward funding the commercialization of its Vykat XR therapy, among others.

The company's shares were down 6.2% in recent Thursday trading.

Price: 85.90, Change: -2.60, Percent Change: -2.93